EP1397489A4 - Tissue-specific and pathogen-specific toxic agents, ribozymes, dnazymes and antisense oligonucleotides, and methods of use thereof - Google Patents
Tissue-specific and pathogen-specific toxic agents, ribozymes, dnazymes and antisense oligonucleotides, and methods of use thereofInfo
- Publication number
- EP1397489A4 EP1397489A4 EP01926973A EP01926973A EP1397489A4 EP 1397489 A4 EP1397489 A4 EP 1397489A4 EP 01926973 A EP01926973 A EP 01926973A EP 01926973 A EP01926973 A EP 01926973A EP 1397489 A4 EP1397489 A4 EP 1397489A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- specific
- dnazymes
- ribozymes
- pathogen
- tissue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06001413A EP1702983A3 (en) | 2000-04-13 | 2001-04-13 | Tissue-specific and pathogen-specific toxic agents, ribozymes, DNAzymes and antisense oligonucleotides and methods of use thereof |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US54844900A | 2000-04-13 | 2000-04-13 | |
US548449 | 2000-04-13 | ||
US25181000P | 2000-12-07 | 2000-12-07 | |
US251810P | 2000-12-07 | ||
PCT/US2001/012130 WO2001079524A2 (en) | 2000-04-13 | 2001-04-13 | Tissue-specific and pathogen-specific toxic agents, ribozymes, dnazymes and antisense oligonucleotides, and methods of use thereof |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP06001413A Division EP1702983A3 (en) | 2000-04-13 | 2001-04-13 | Tissue-specific and pathogen-specific toxic agents, ribozymes, DNAzymes and antisense oligonucleotides and methods of use thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1397489A2 EP1397489A2 (en) | 2004-03-17 |
EP1397489A4 true EP1397489A4 (en) | 2005-05-11 |
Family
ID=26941841
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP01926973A Withdrawn EP1397489A4 (en) | 2000-04-13 | 2001-04-13 | Tissue-specific and pathogen-specific toxic agents, ribozymes, dnazymes and antisense oligonucleotides, and methods of use thereof |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1397489A4 (en) |
JP (1) | JP2004525602A (en) |
AU (2) | AU2001253471B2 (en) |
CA (1) | CA2406403A1 (en) |
WO (1) | WO2001079524A2 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8183011B2 (en) * | 2003-06-13 | 2012-05-22 | University Of Medicine And Dentistry Of New Jersey | RNA interferases and methods of use thereof |
WO2005046579A2 (en) * | 2003-10-06 | 2005-05-26 | Gangagen, Inc. | Defined dose therapeutic phage |
WO2015101416A1 (en) | 2013-12-30 | 2015-07-09 | Curevac Gmbh | Methods for rna analysis |
US20210022324A1 (en) * | 2018-03-05 | 2021-01-28 | Dr. Reddy's Institute Of Life Sciences | Embryonic zebrafish models using dnazyme mediated knockdown |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991008312A1 (en) * | 1989-12-01 | 1991-06-13 | Gene-Trak Systems | Detection of hpv transcripts |
WO1993023569A1 (en) * | 1992-05-11 | 1993-11-25 | Ribozyme Pharmaceuticals, Inc. | Method and reagent for inhibiting viral replication |
WO1994026934A2 (en) * | 1993-05-06 | 1994-11-24 | Baxter Diagnostics Inc. | Human papillomavirus detection assay |
WO1997003211A1 (en) * | 1995-07-13 | 1997-01-30 | Isis Pharmaceuticals, Inc. | Antisense inhibition of hepatitis b virus replication |
WO2000009673A1 (en) * | 1998-08-13 | 2000-02-24 | Johnson & Johnson Research Pty. Limited | Dnazymes and methods for treating hpv-related disorders |
WO2002046449A2 (en) * | 2000-12-07 | 2002-06-13 | The Penn State Research Foundation | Selection of catalytic nucleic acids targeted to infectious agents |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9015845D0 (en) * | 1990-07-19 | 1990-09-05 | Emery Vincent C | Diagnostic method |
FR2679254B1 (en) * | 1991-07-17 | 1993-11-19 | Clonatec | OLIGONUCLEOTIDE PROBES FOR THE TYPING AND DETECTION OF HUMAN PAPILLOMAVIRUSES. |
US5767259A (en) * | 1994-12-27 | 1998-06-16 | Naxcor | Oligonucleotides containing base-free linking groups with photoactivatable side chains |
US6015686A (en) * | 1993-09-15 | 2000-01-18 | Chiron Viagene, Inc. | Eukaryotic layered vector initiation systems |
US5989804A (en) * | 1994-07-08 | 1999-11-23 | New England Medical Center Hospitals, Inc. | E6 binding proteins |
-
2001
- 2001-04-13 AU AU2001253471A patent/AU2001253471B2/en not_active Ceased
- 2001-04-13 JP JP2001577507A patent/JP2004525602A/en active Pending
- 2001-04-13 WO PCT/US2001/012130 patent/WO2001079524A2/en active IP Right Grant
- 2001-04-13 CA CA002406403A patent/CA2406403A1/en not_active Abandoned
- 2001-04-13 EP EP01926973A patent/EP1397489A4/en not_active Withdrawn
- 2001-04-13 AU AU5347101A patent/AU5347101A/en active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991008312A1 (en) * | 1989-12-01 | 1991-06-13 | Gene-Trak Systems | Detection of hpv transcripts |
WO1993023569A1 (en) * | 1992-05-11 | 1993-11-25 | Ribozyme Pharmaceuticals, Inc. | Method and reagent for inhibiting viral replication |
WO1994026934A2 (en) * | 1993-05-06 | 1994-11-24 | Baxter Diagnostics Inc. | Human papillomavirus detection assay |
WO1997003211A1 (en) * | 1995-07-13 | 1997-01-30 | Isis Pharmaceuticals, Inc. | Antisense inhibition of hepatitis b virus replication |
WO2000009673A1 (en) * | 1998-08-13 | 2000-02-24 | Johnson & Johnson Research Pty. Limited | Dnazymes and methods for treating hpv-related disorders |
WO2002046449A2 (en) * | 2000-12-07 | 2002-06-13 | The Penn State Research Foundation | Selection of catalytic nucleic acids targeted to infectious agents |
Non-Patent Citations (12)
Title |
---|
ALVAREZ-SALAS L M ET AL: "Inhibition of HPV-16 E6/E7 immortalization of normal keratinocytes by hairpin ribozymes.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 3 FEB 1998, vol. 95, no. 3, 3 February 1998 (1998-02-03), pages 1189 - 1194, XP002317756, ISSN: 0027-8424 * |
CHEN Z ET AL: "EFFECTIVENESS OF THREE RIBOZYMES FOR CLEAVAGE OF AN RNA TRANSCRIPT FROM HUMAN PAPILLOMAVIRUS TYPE 18", CANCER GENE THERAPY, NORWALK, CT, US, vol. 2, no. 4, 1995, pages 263 - 271, XP008040034, ISSN: 0929-1903 * |
DIAZ-FLORES ESTEVEZ F ET AL: "Detection of human Papillomavirus types 6b, 11, 16 and 18 in cervical scrapes by a multiplex polymerase chain reaction", REVISTA DE LA SOCIEDAD ESPANOLA DE QUIMICA CLINICA 1996 SPAIN, vol. 15, no. 6, 1996, pages 420 - 424, XP001203827, ISSN: 0213-8514 * |
JI W ET AL: "Inhibition of hepatitis B virus by retroviral vectors expressing antisense RNA.", JOURNAL OF VIRAL HEPATITIS. MAY 1997, vol. 4, no. 3, May 1997 (1997-05-01), pages 167 - 173, XP002317755, ISSN: 1352-0504 * |
PAN WEI-HUA ET AL: "A selection system for identifying accessible sites in target RNAs", RNA (NEW YORK), vol. 7, no. 4, April 2001 (2001-04-01), pages 610 - 621, XP002317752, ISSN: 1355-8382 * |
PASSMAN M ET AL: "In situ demonstration of inhibitory effects of hammerhead ribozymes that are targeted to the hepatitis Bx sequence in cultured cells.", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS. 24 FEB 2000, vol. 268, no. 3, 24 February 2000 (2000-02-24), pages 728 - 733, XP002317754, ISSN: 0006-291X * |
PLOURDE ROBERT ET AL: "Targeted therapy for viral hepatitis", ADVANCED DRUG DELIVERY REVIEWS, vol. 17, no. 3, 1995, pages 311 - 315, XP002317757, ISSN: 0169-409X * |
See also references of WO0179524A3 * |
STEELE C ET AL: "EFFECTS OF HUMAN PAPILLOMAVIRUS TYPE 18-SPECIFIC ANTISENSE OLIGONUCLEOTIDES ON THE TRANSFORMED PHENOTYPE OF HUMAN CARCINOMA CELL LINES", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 53, no. 10, 15 May 1993 (1993-05-15), pages 2330 - 2337, XP002030937, ISSN: 0008-5472 * |
VENTURINI FRANCESCA ET AL: "Kinetic selection of HPV 16 E6/E7-directed antisense nucleic acids: Anti-proliferative effects on HPV 16-transformed cells", NUCLEIC ACIDS RESEARCH, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 27, no. 7, 1 April 1999 (1999-04-01), pages 1585 - 1592, XP002234550, ISSN: 0305-1048 * |
WEIZSAECKER VON F ET AL: "CLEAVAGE OF HEPATITIS B VIRUS RNA BY THREE RIBOZYMES TRANSCRIBED FROM A SINGLE DNA TEMPLATE", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 189, no. 2, 15 December 1992 (1992-12-15), pages 743 - 748, XP000652045, ISSN: 0006-291X * |
WELCH P J ET AL: "Intracellular application of hairpin ribozyme genes against hepatitis B virus.", GENE THERAPY. JUL 1997, vol. 4, no. 7, July 1997 (1997-07-01), pages 736 - 743, XP002317753, ISSN: 0969-7128 * |
Also Published As
Publication number | Publication date |
---|---|
AU5347101A (en) | 2001-10-30 |
EP1397489A2 (en) | 2004-03-17 |
AU2001253471B2 (en) | 2007-07-26 |
WO2001079524A2 (en) | 2001-10-25 |
JP2004525602A (en) | 2004-08-26 |
WO2001079524A3 (en) | 2004-01-08 |
CA2406403A1 (en) | 2001-10-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL143379A0 (en) | ANTISENSE OLIGONUCLEOTIDE AGAINST HUMAN AChE AND USES THEREOF | |
HUP0204118A3 (en) | 4-aminopicolinates and their use as herbicides | |
AU2925401A (en) | Methods and compositions for antisense vegf oligonucleotides | |
IL154409A0 (en) | Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers | |
IL152549A0 (en) | Vectors for ocular transduction and use thereof for genetic therapy | |
HUP0301049A3 (en) | Personal cleansing bar and preparation process | |
AU1194802A (en) | DNA expression vectors and methods of use | |
MXPA03004915A (en) | Mch antagonists and their use in the treatment of obesity. | |
MXPA03002273A (en) | Shampoo and body wash composition. | |
HUP0302069A3 (en) | Selective and synergistic herbicidal compositions containing heteroaryloxy-acetamide-derivatives, preparation and use thereof | |
HUP0203818A3 (en) | Fungicidal trifluoromethylpyrrole carboxamides and trifluoromethylpyrrolethioamides, preparation and use thereof | |
SI1337521T1 (en) | Salts of an isothiazole-4-carboxamide and their use as anti-hyperproliferation agents | |
HK1053130A1 (en) | Caveolin peptides and their use as therapeutics | |
EP1102786A4 (en) | Low adenosine anti-sense oligonucleotide agent, composition, kit and treatments | |
AU6723401A (en) | Antimicrobial peptides and methods of use thereof | |
AU7614901A (en) | Cleaning and disinfecting agent | |
GB0022710D0 (en) | Dispenser and method of use | |
AU5347101A (en) | Tissue-specific and pathogen-specific toxic agents, ribozymes, dnazymes and antisense oligonucleotides, and methods of use thereof | |
IL150882A0 (en) | Arylpiperazines and arylpiperidines and their use as metalloproteinase inhibiting agents | |
HUP0304092A3 (en) | Combination of active agents with bioregulatory effect and use thereof | |
GB0010318D0 (en) | Improvements in catalytic reduction of NoÎ | |
HUP0303682A3 (en) | Herbicide composition, preparation and use thereof | |
GB0007530D0 (en) | Trityl-type compounds and their use | |
GB0030067D0 (en) | Therapeutic agent | |
HUP0301119A3 (en) | Biologically active agent and drug |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20021113 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: 7C 12N 15/11 A Ipc: 7C 12N 15/74 B |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20050321 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20060125 |